BioCentury | May 16, 2019
Company News

May 16 Company Quick Takes: Iconic oncology deals; plus Zymeworks-GSK, Aimmune and more

...Bison Capital complete merger Cancer company Xynomic Pharmaceuticals Holdings Inc. (NASDAQ:XYN) completed its reverse merger with Bison Capital...
...Acquisition Corp. Wednesday. BioCentury Staff AR101, arc001, peanut allergy oral immunotherapy (oit) ICON-2 Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Aimmune Therapeutics Inc. Bison Capital...
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...CNS therapeutics targeting neuronal nicotinic receptors 2003 $60M series B, 2003 Academy Ventures; Auriga Ventures; Bison Capital...
BioCentury | Apr 19, 2004
Emerging Company Profile

Corporate Profile

...Associates; Oxford Bioscience Partners; Advent Venture Partners; Burrill & Co.; Academy Venture Fund; Auriga Ventures; Bison Capital...
BioCentury | Mar 29, 2004
Strategy

All that Jazz . . .

...Stage Capital Targacept $60.0 3/19/03 Neurology Nomura International; Oxford Bioscience Partners; JAFCO; Cogene Biotech Ventures; Bison Capital...
BioCentury | Mar 24, 2003
Finance

Ebb & Flow

...second tranche was led by Nomura and included Oxford Bioscience Partners; JAFCO; Cogene Biotech Ventures; Bison Capital...
BioCentury | Mar 19, 2003
Financial News

Targacept raises additional $14 million

...lead investor was Nomura International. Other investors included Oxford Bioscience Partners; JAFCO; Cogene Biotech Ventures; Bison Capital...
Items per page:
1 - 6 of 6
BioCentury | May 16, 2019
Company News

May 16 Company Quick Takes: Iconic oncology deals; plus Zymeworks-GSK, Aimmune and more

...Bison Capital complete merger Cancer company Xynomic Pharmaceuticals Holdings Inc. (NASDAQ:XYN) completed its reverse merger with Bison Capital...
...Acquisition Corp. Wednesday. BioCentury Staff AR101, arc001, peanut allergy oral immunotherapy (oit) ICON-2 Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Aimmune Therapeutics Inc. Bison Capital...
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...CNS therapeutics targeting neuronal nicotinic receptors 2003 $60M series B, 2003 Academy Ventures; Auriga Ventures; Bison Capital...
BioCentury | Apr 19, 2004
Emerging Company Profile

Corporate Profile

...Associates; Oxford Bioscience Partners; Advent Venture Partners; Burrill & Co.; Academy Venture Fund; Auriga Ventures; Bison Capital...
BioCentury | Mar 29, 2004
Strategy

All that Jazz . . .

...Stage Capital Targacept $60.0 3/19/03 Neurology Nomura International; Oxford Bioscience Partners; JAFCO; Cogene Biotech Ventures; Bison Capital...
BioCentury | Mar 24, 2003
Finance

Ebb & Flow

...second tranche was led by Nomura and included Oxford Bioscience Partners; JAFCO; Cogene Biotech Ventures; Bison Capital...
BioCentury | Mar 19, 2003
Financial News

Targacept raises additional $14 million

...lead investor was Nomura International. Other investors included Oxford Bioscience Partners; JAFCO; Cogene Biotech Ventures; Bison Capital...
Items per page:
1 - 6 of 6